Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia

Trial Profile

Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Vincristine (Primary) ; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Imatinib; Mesna; Methotrexate; Methylprednisolone sodium succinate; Pegfilgrastim; Rituximab
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2015 Results (n=27) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 09 Sep 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 25 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top